{"id":39319,"date":"2025-08-14T14:11:16","date_gmt":"2025-08-14T06:11:16","guid":{"rendered":"https:\/\/flcube.com\/?p=39319"},"modified":"2025-08-14T14:11:17","modified_gmt":"2025-08-14T06:11:17","slug":"jiangsu-hengrui-establishes-new-biopharmaceutical-unit-to-strengthen-anesthesia-and-icu-presence","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39319","title":{"rendered":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence"},"content":{"rendered":"\n

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276<\/a>, SHA: 600276<\/a>)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.<\/p>\n\n\n\n

Background of the BBU<\/strong>
In January 2024, Hengrui merged its former Comprehensive Product Business Unit and Imaging Business Unit to form a new Comprehensive Business Unit. This unit focuses on areas such as metabolism, autoimmune diseases, imaging, weight management, and respiratory conditions. Over the past year, the Comprehensive Business Unit has shown significant performance improvements. Its flagship product, Henagliflozin, has seen its market share continue to climb, surpassing Merck to rank second in the domestic SGLT2 product market. The unit has also had several Class 1 new drugs approved for market launch, indicating a positive development trend.<\/p>\n\n\n\n

Biopharmaceutical Business Unit (BBU)<\/strong>
The newly established BBU will oversee more than 10 Class 1 innovative drugs that have already been marketed. These drugs cover areas such as metabolism, autoimmune diseases, pain relief, anesthesia, and critical care. In the recently announced initial screening list for national drug negotiations, several of its Class 1 innovative drugs passed the initial screening. These include key products such as its interleukin-17A inhibitor, JAK-1 inhibitor, and an ultra-long-acting PCSK9 inhibitor.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025,…<\/p>\n","protected":false},"author":1,"featured_media":39328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2586,4228,852],"class_list":["post-39319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"\nJiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39319\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39319\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T06:11:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T06:11:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence\",\"datePublished\":\"2025-08-14T06:11:16+00:00\",\"dateModified\":\"2025-08-14T06:11:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1404.webp\",\"keywords\":[\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39319#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39319\",\"name\":\"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1404.webp\",\"datePublished\":\"2025-08-14T06:11:16+00:00\",\"dateModified\":\"2025-08-14T06:11:17+00:00\",\"description\":\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39319\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39319#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39319","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence","og_description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.","og_url":"https:\/\/flcube.com\/?p=39319","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-14T06:11:16+00:00","article_modified_time":"2025-08-14T06:11:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39319#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39319"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence","datePublished":"2025-08-14T06:11:16+00:00","dateModified":"2025-08-14T06:11:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39319"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","keywords":["Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39319#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39319","url":"https:\/\/flcube.com\/?p=39319","name":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39319#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","datePublished":"2025-08-14T06:11:16+00:00","dateModified":"2025-08-14T06:11:17+00:00","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276)\u00a0 announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39319#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39319"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39319#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39319#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39319"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39319\/revisions"}],"predecessor-version":[{"id":39329,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39319\/revisions\/39329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39328"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}